CN102680688A - 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 - Google Patents
诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 Download PDFInfo
- Publication number
- CN102680688A CN102680688A CN2012101491618A CN201210149161A CN102680688A CN 102680688 A CN102680688 A CN 102680688A CN 2012101491618 A CN2012101491618 A CN 2012101491618A CN 201210149161 A CN201210149161 A CN 201210149161A CN 102680688 A CN102680688 A CN 102680688A
- Authority
- CN
- China
- Prior art keywords
- bfar
- diagnostic kit
- solution
- serum
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 51
- 102100026151 Bifunctional apoptosis regulator Human genes 0.000 title claims abstract description 33
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 206010017758 gastric cancer Diseases 0.000 title abstract description 19
- 201000011549 stomach cancer Diseases 0.000 title abstract description 18
- 101710157912 Bifunctional apoptosis regulator Proteins 0.000 title abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 44
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 16
- 108090000790 Enzymes Proteins 0.000 claims abstract description 16
- 238000013399 early diagnosis Methods 0.000 claims abstract description 13
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 238000005406 washing Methods 0.000 claims abstract description 4
- 201000000498 stomach carcinoma Diseases 0.000 claims description 37
- 101000764928 Homo sapiens Bifunctional apoptosis regulator Proteins 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 9
- 238000007865 diluting Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 7
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000001261 affinity purification Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 229960002163 hydrogen peroxide Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- -1 standard serum Proteins 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 27
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 239000000090 biomarker Substances 0.000 abstract description 6
- 108090000144 Human Proteins Proteins 0.000 abstract description 4
- 102000003839 Human Proteins Human genes 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000007789 sealing Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000006193 liquid solution Substances 0.000 abstract 1
- 239000012089 stop solution Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 208000010749 gastric carcinoma Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000036292 Death effector domains Human genes 0.000 description 1
- 108091010866 Death effector domains Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210149161.8A CN102680688B (zh) | 2012-05-14 | 2012-05-14 | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210149161.8A CN102680688B (zh) | 2012-05-14 | 2012-05-14 | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102680688A true CN102680688A (zh) | 2012-09-19 |
CN102680688B CN102680688B (zh) | 2014-07-02 |
Family
ID=46812931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210149161.8A Active CN102680688B (zh) | 2012-05-14 | 2012-05-14 | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102680688B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101389962A (zh) * | 2005-12-28 | 2009-03-18 | 韩国生命工学研究院 | 用于诊断胃癌的作为标记的mac-2bp |
CN101493463A (zh) * | 2008-01-24 | 2009-07-29 | 上海交通大学医学院附属瑞金医院 | 胃癌诊断试剂及其用途 |
WO2011097960A1 (en) * | 2010-02-11 | 2011-08-18 | The Hong Kong Polytechnic University | Biomarkers of gastric cancer and use thereof |
US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
-
2012
- 2012-05-14 CN CN201210149161.8A patent/CN102680688B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101389962A (zh) * | 2005-12-28 | 2009-03-18 | 韩国生命工学研究院 | 用于诊断胃癌的作为标记的mac-2bp |
CN101493463A (zh) * | 2008-01-24 | 2009-07-29 | 上海交通大学医学院附属瑞金医院 | 胃癌诊断试剂及其用途 |
WO2011097960A1 (en) * | 2010-02-11 | 2011-08-18 | The Hong Kong Polytechnic University | Biomarkers of gastric cancer and use thereof |
US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
Non-Patent Citations (2)
Title |
---|
MICHELE BIANCHINI, ET AL.: "Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa.", 《INTERNATIONAL JOURNAL OF ONCOLOGY》, vol. 29, no. 1, 1 July 2006 (2006-07-01), pages 83 - 94 * |
李红梅,等: "BFAR与p75NTR的蛋白相互作用抑制p75NTR信号转导", 《中国科学:生命科学》, vol. 41, no. 12, 31 December 2011 (2011-12-31), pages 1140 - 1147 * |
Also Published As
Publication number | Publication date |
---|---|
CN102680688B (zh) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Early detection of SARS-CoV-2 seroconversion in humans with aggregation-induced near-infrared emission nanoparticle-labeled lateral flow immunoassay | |
CN102680709B (zh) | 诊断试剂盒及ccdc49在制备胃癌早期诊断试剂中的应用 | |
CN103547923B (zh) | 乳腺癌的生物标记 | |
Mossad et al. | Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma | |
CN109342727B (zh) | 食管鳞状细胞癌自身抗体分子标志物模型及其应用 | |
CN102680706B (zh) | 蛋白质ctsf在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
Nyström et al. | Type IV collagen as a tumour marker for colorectal liver metastases | |
CN110187109A (zh) | 一种用于贲门腺癌早期筛查的自身抗体联合检测elisa试剂盒 | |
WO2016029117A1 (en) | Methods for the early detection of colorectal cancer | |
EP3516399B1 (en) | Diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a) | |
CN101344526A (zh) | 一种快速、精确的前列腺癌的检测试纸条及其制备和应用 | |
CN107462725B (zh) | 抗FNDC4的IgG抗体作为胃癌血清标志物的应用及其试剂盒 | |
CN105092846A (zh) | Thbs2作为直肠癌血清标记物的应用及诊断试剂盒 | |
CN105424941A (zh) | Akr1b10蛋白和用于肝硬化诊断的试剂盒 | |
CN102680708B (zh) | 诊断试剂盒及rnf19在制备胃癌早期诊断试剂中的应用 | |
CN102680688A (zh) | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 | |
CN102680687A (zh) | 蛋白质terf1在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN102798722A (zh) | 蛋白质nt5e在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN102375064A (zh) | 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒 | |
CN104330570A (zh) | 人热休克蛋白gp96在制备筛查肝病的产品中的应用 | |
CN102680707B (zh) | 蛋白质cops2在制备诊断胃癌的试剂中的应用及诊断试剂盒 | |
CN107449903B (zh) | 抗XRCC3的IgG抗体作为胃癌血清标志物的应用及其试剂盒 | |
CN110261618B (zh) | Sprr4蛋白作为胃癌血清生物标志物的应用及其试剂盒 | |
CN102971630A (zh) | 非酒精性脂肪性肝炎检测和/或鉴别用标记物、检测和/或鉴别非酒精性脂肪性肝炎的方法及用于它们的试剂盒 | |
CN107543929A (zh) | 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120919 Assignee: CHENGDU CAPITALBIO NEW VIEW DIAGNOSTIC TECHNOLOGY Co.,Ltd. Assignor: Shanghai Jiao Tong University Contract record no.: 2016990000394 Denomination of invention: Diagnostic kit and application of BFAR (bifunctional apoptosis regulator) in preparation of gastric cancer early diagnostic reagent Granted publication date: 20140702 License type: Exclusive License Record date: 20160913 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: CHENGDU CAPITALBIO NEW VIEW DIAGNOSTIC TECHNOLOGY Co.,Ltd. Assignor: SHANGHAI JIAO TONG University Contract record no.: 2016990000394 Date of cancellation: 20231229 |
|
EC01 | Cancellation of recordation of patent licensing contract |